Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) belonging to the Medical sector has declined -7.36% and closed its last trading session at $3.4.
The company reported its EPS on 11/09/2016. Currently, the stock has a 1 Year Price Target of $9.
The consensus recommendation, according to Zacks Investment research, is 3. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 3 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.5 and 2.33 respectively.
Merrimack Pharmaceuticals, Inc. on 11/09/2016 reported its EPS as $-0.23 with the analysts projecting the EPS of the stock as $-0.27. The company beat the analyst EPS Estimate with the difference of $0.04. This shows a surprise factor of 14.8%.
Many analysts have provided their estimated foresights on Merrimack Pharmaceuticals, Inc. Earnings, with 4 analysts believing the company would generate an Average Estimate of $-0.21. Whereas they predicted High and Low Earnings Estimate as $-0.14 and $-0.35 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.41.
Analysts are also projecting an Average Revenue Estimate for Merrimack Pharmaceuticals, Inc. as $61.07 Million in the Current Quarter. This estimate is provided by 4 analysts. The High Revenue estimate is predicted as 104.1 Million, while the Low Revenue Estimate prediction stands at 19 Million. The company’s last year sales total was 21.42 Million.
The Company got Downgrade by JP Morgan on 7-Oct-16 from Overweight to Neutral.
Insider Trades for Merrimack Pharmaceuticals, Inc. show that the latest trade was made on 25 Jul 2016 where Stewart (Edward J), the Officer completed a transaction type “Buy” in which 30000 shares were traded at a price of $2.47.
Over the period of 6 months, Insider Purchases show a total of 6 transaction in which 156284 shares were traded. 18 Insider Sales transactions were made totaling 268000 shares traded.
3 analysts projected Price Targets for Merrimack Pharmaceuticals, Inc.. The analysts believe that the company stock price could grow as high as $15. The Low Price target projection by analysts is $5 and the Mean Price Target is $9.
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) has the market capitalization of $465.15 Million. The company rocked its 52-Week High of $9.02 on Apr 7, 2016 and touched its 52-Week Low of $3.3 on Jan 10, 2017. The stock has Return on Assets (ROA) of -96 percent. Return on Equity (ROE) stands at 80.6% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of -16.67 Percent. The company has Beta Value of 1.93 and ATR value of 0.37. The Weekly and Monthly Volatility stands at 14.58% and 7.52%.
Merrimack Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery, development and preparation to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with a special focus on cancer. Merrimack Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.